40203-94-9

Basic information

• Product Name: (S)-2-ISOCYANATO-3-PHENYLPROPIONIC ACID METHYL ESTER
• Synonyms: METHYL (S)-(-)-2-ISOCYANATO-3-PHENYLPROPIONATE;METHYL (S)-2-ISOCYANATO-3-PHENYLPROPIONATE;METHYL 2(S)-ISOCYANATO-3-PHENYLPROPANOATE;(S)-2-ISOCYANATO-3-PHENYLPROPIONIC ACID METHYL ESTER;(S)-2-Isocyanato-3-phenylpropionic Acid;(S)-2-ISOCYANATO-3-PHENYLPROPIONIC ACID METHYL ESTER 95+%;methyl-(s)-2-isocyanato-3-phenylpropanate;methyl N-(oxomethylene)phenylalaninate
• CAS NO: 40203-94-9
• Molecular Formula: C₁₁H₁₁NO₃
• Molecular Weight: 205.21
• Product Categories: pharmacetical;Chiral Building Blocks;Isocyanates (Chiral);Synthetic Organic Chemistry;Chiral Building Blocks;Isocyanates;Organic Building Blocks
• Mol File: 40203-94-9.mol

Chemical Properties

• Melting Point: 23°C
• Boiling Point: 244 °C(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.13 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00178mmHg at 25°C
• Refractive Index: n20/D 1.513(lit.)
• CAS DataBase Reference: (S)-2-ISOCYANATO-3-PHENYLPROPIONIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-ISOCYANATO-3-PHENYLPROPIONIC ACID METHYL ESTER(40203-94-9)
• EPA Substance Registry System: (S)-2-ISOCYANATO-3-PHENYLPROPIONIC ACID METHYL ESTER(40203-94-9)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36
• RIDADR: UN 2206 6.1/PG 3
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 40203-94-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-ISOCYANATO-3-PHENYLPROPIONIC ACID METHYL ESTER is used as a key intermediate for the synthesis of dipeptide analogs of angiotensinogen. These analogs play a crucial role in the development of drugs targeting the renin-angiotensin system, which is involved in regulating blood pressure and fluid balance in the body.
Additionally, this compound is used in the preparation of Schiff base derivatives, which are important in the inhibition of thermolysin. Thermolysin is a proteolytic enzyme that has been implicated in various pathological conditions, and its inhibition can be beneficial in the treatment of such diseases.

InChI:InChI=1/C11H11NO3/c1-15-11(14)10(12-8-13)7-9-5-3-2-4-6-9/h2-6,10H,7H2,1H3

Upstream product

• 75-44-5 phosgene 
• 5619-07-8 methyl 2-amino-3-phenylpropanoate hydrochloride 
• 51987-73-6 (S)-2-tert-butoxycarbonylamino-3-phenyl-propionic acid methyl ester 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 63-91-2 L-phenylalanine 
• 35909-92-3 N-carbobenzoxy-L-phenylalanine methyl ester 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 503-38-8 trichloromethyl chloroformate 

Downstream Products

• 883973-92-0 (S)-2-[3-(2-Benzyloxy-ethyl)-3-methyl-ureido]-3-phenyl-propionic acid methyl ester 
• 883973-30-6 (S)-2-(3-Benzyl-3-isopropyl-ureido)-3-phenyl-propionic acid methyl ester 
• 1352564-02-3 methyl (S)-2-{3-[3,5-bis(trifluoromethyl)phenyl]ureido}-3-phenylpropanoate 
• 1354894-22-6 (S)-methyl 2-((((4-ethynylbenzyl)oxy)carbonyl)amino)-3-phenylpropanoate 
• 1354894-21-5 (S)-3-phenyl-2-(4-(prop-2-yn-1-yl)piperazine-1-carboxamido)propanoic acid hydrochloride 
• 1354894-16-8 N-((S)-1-oxo-3-phenyl-1-(((S,E)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl)amino)propan-2-yl)-4-(prop-2-yn-1-yl)piperazine-1-carboxamide 
• 1354894-23-7 (S)-2-((((4-ethynylbenzyl)oxy)carbonyl)amino)-3-phenylpropanoic acid 
• 1354894-17-9 4-ethynylbenzyl((S)-1-oxo-3-phenyl-1-(((S,E)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl)amino)propan-2-yl)carbamate 
• 1452877-15-4 (R)-methyl 3-phenyl-2-(3-(pyridin-2-yl)ureido)propanoate 
• 125369-25-7 methyl (2S)-2-{[(benzylamino)carbonyl]amino}-3-phenylpropanoate 

Relevant articles and documents

Heterocyclic amide compound, pharmaceutical composition containing heterocyclic amide compound, preparation method of heterocyclic amide compound and application of heterocyclic amide compound

The invention relates to a heterocyclic amide compound, a pharmaceutical composition containing the heterocyclic amide compound, a preparation method of the heterocyclic amide compound and an application of the heterocyclic amide compound serving as an agonist of stimulator of interferon gene (STING). More specifically, the invention relates to the heterocyclic amide compound; the heterocyclic amide compound is capable of stimulating the production of interferon, thereby being used as an immunomodulator for treatment of STING-mediated diseases or disease conditions such as cancer, infectious diseases, inflammation, immune-related diseases and the like.

THIOSEMICARBAZATES AND USES THEREOF

Thioesters, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides; and a chemoselective and site-specific functionalization protocol of protected thiocarbazates and semithiocarbazates are described. The protocol features the use of Mitsunobu reaction to alkylate specifically the nitrogen atom close to the acylthiol moiety with alcohols to produce protected mono-substituted thiocarbazates that can be stored for months, activated under mild conditions at low temperature using halonium reagents and integrated orthogonally to make substituted semicarbazides that can be used, e.g., as synthons in synthesis of aza-amino acid conjugates, azapeptides and other peptidomimetics. Methods for preparing and using ureases, carbazides, semicarbazides, beta-peptides, azapeptides, and other peptidomimetics and azapeptide conjugates, and uses of ureases, carbazides, semicarbazides, beta-peptides, azapeptides in drug discovery, diagnosis, inhibition, prevention and treatment of diseases are also described.

PF74 and its novel derivatives stabilize hexameric lattice of HIV-1 mature-like particles

A major structural retroviral protein, capsid protein (CA), is able to oligomerize into two different hexameric lattices, which makes this protein a key component for both the early and late stages of HIV-1 replication. During the late stage, the CA prote

Synthesis of N-Acylamino-Acid Derivatives of Cytisine

N-acylamino-acid derivatives of cytisine were prepared by reacting cytisine with methyl esters of aminoacid isocyanates.

One-pot synthesis of ureas from Boc-protected amines

A practical one-pot synthesis of ureas is described. Boc-protected amines can be transformed into nonsymmetrical and symmetrical disubstituted and trisubstituted ureas utilizing 2-chloropyridine and trifluoromethanesulfonyl anhydride for the in situ generation of an isocyanate, which reacts with an amine. A variety of amines can be employed successfully, leading to high yields of isolated ureas.

Inhibition of norovirus 3CL protease by bisulfite adducts of transition state inhibitors

Noroviruses are the most common cause of acute viral gastroenteritis, accounting for >21 million cases annually in the US alone. Norovirus infections constitute an important health problem for which there are no specific antiviral therapeutics or vaccines. In this study, a series of bisulfite adducts derived from representative transition state inhibitors (dipeptidyl aldehydes and α-ketoamides) was synthesized and shown to exhibit anti-norovirus activity in a cell-based replicon system. The ED 50 of the most effective inhibitor was 60 nM. This study demonstrates for the first time the utilization of bisulfite adducts of transition state inhibitors in the inhibition of norovirus 3C-like protease in vitro and in a cell-based replicon system. The approach described herein can be extended to the synthesis of the bisulfite adducts of other classes of transition state inhibitors of serine and cysteine proteases, such as α-ketoheterocycles and α-ketoesters.

Synthesis of a new urea derivative: A dual-functional organocatalyst for Knoevenagel condensation in water

A phenylalanine-urea compound-catalyzed Knoevenagel condensation in water is reported. Various aldehydes and active methylene compounds undergo condensation at room temperature to give the desired products in high yields. The mechanism of the condensation of aldehydes with Meldrum's acid catalyzed by the novel urea derivative is also disclosed.

Proteomic profiling and potential cellular target identification of K11777, a clinical cysteine protease inhibitor, in Trypanosoma brucei

We report herein the design, synthesis and application of K11777-derived activity-based probes (ABPs) allowing in situ profiling and identification of potential cellular targets of K11777 in Trypanosoma brucei.

Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors

A series of amino acid ureido derivatives as aminopeptidase N (APN/CD13) inhibitors were synthesized and evaluated for their APN inhibitory activities and anti-cancer effects. The results showed that most of these amino acid ureido derivatives exhibited good inhibition against APN, several of which were better than Bestatin. The most active compound 12j (IC50 = 1.1 μM, compared with Bestatin IC50 = 8.1 μM) not only possessed much better APN inhibitory activity and anti-proliferation effect on cancer cells, but also exhibited significant block effect of human cancer cell invasion compared with the positive control, Bestatin. These amino acid ureido derivatives could be possibly developed as new APN inhibitors for cancer chemotherapy in the future.

Hydantoin-free synthesis of peptide ester isocyanates, isothiocyanates, and dipeptidyl ureas: The application of zinc dust in a carbonylation procedure without base

Non-Schotten-Baumann conditions are described for the hydantoin-free synthesis of peptide ester isocyanates using activated zinc dust as a non-basic HCl scavenger. Also, the procedure gives no N-acylated products in the case of the conversion of amino acid and peptide amides into isocyanates. Georg Thieme Verlag Stuttgart · New York.